

# Clinical trials of CEPT inhibition for cardiovascular prevention in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 ACAT inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>evacetrapib vs atorvastatine</b>			
<b>ACCENTUATE</b> <i>ongoing</i> [NCT02227784] n=NA follow-up:	Atorvastatin + Evacetrapib for 90 days versus Atorvastatin (40mg alone, 80 mg alone or in combination with ezetimibe)	-	double-blind
<b>anacetrapib vs placebo</b>			
<b>DEFINE</b> , 2010 [NCT00685776] n=811/812 follow-up:	anacetrapib 100mg fr 18 months versus placebo	patients with coronary heart disease or at high risk for coronary heart disease	Parallel groups double-blind 20 countries
<b>REVEAL HPS-3 TIMI-55</b> <i>ongoing</i> [NCT01252953] n=NA	-	-	
<b>dalcetrapib vs placebo</b>			
<b>dal-VESSEL</b> , 2011 n=NA follow-up: 12 weeks	dalcetrapib 600 mg daily versus placebo	men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL	Parallel groups double-blind
<b>dal-OUTCOMES</b> , 2012 [NCT00658515] n=7938/7933 follow-up: 31 montsh (median)	dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event versus placebo	patients with recent acute coronary syndrome	Parallel groups double-blind 27 countries
<b>evacetrapib vs placebo</b>			
<b>ACCELERATE</b> , 2015 [NCT01687998] n=12095 follow-up:	evacetrapib versus placebo	Patients at a High-Risk for Vascular Outcomes	Parallel groups 37 countries
<b>torcetrapib vs placebo (on top of atorvastatin)</b>			
<b>RADIANCE 1</b> , 2007 [NCT00136981] n=450/454 follow-up: 24 months	atorvastatin combined with 60 mg of torcetrapib versus atorvastatin monotherapy	patients with heterozygous familial hypercholesterolemia	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
<b>ILLUMINATE , 2007</b> [NCT00134264] n=7533/7534 follow-up: 1.52y	torcetrapib 60mg daily plus atorvastatin (at a dose established during the runin period) versus atorvastatin alone	patients at high cardiovascular risk	Parallel groups double blind 7 countries
<b>RADIANCE 2 , 2007</b> n=377/375 follow-up: 24 months	torcetrapib 60mg daily (on top of atorvastatin attitrated dose) versus placebo +atorvastatin attitrated dose	patients with mixed dyslipidaemia	Parallel groups double blind North America and Europe
<b>ILLUSTRATE , 2007</b> [NCT00134173] n=591/597 follow-up: 24 months	atorvastatin plus 60 mg of torcetrapib daily versus atorvastatin monotherapy	patients with coronary disease	Parallel groups open North America and Europe

## References

### ACCENTUATE, 0:

### DEFINE, 2010:

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N Engl J Med 2010 Nov 17;: [21082868] [10.1056/NEJMoa1009744](https://doi.org/10.1056/NEJMoa1009744)

### REVEAL HPS-3 TIMI-55 , :

### dal-VESSEL, 2011:

### dal-OUTCOMES, 2012:

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec;158:896-901.e3 [19958854]

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012 Nov 5;: [23126252] [10.1056/NEJMoa1206797](https://doi.org/10.1056/NEJMoa1206797)

### ACCELERATE, 2015:

### RADIANCE 1, 2007:

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 Apr 19;356:1620-30 [17387131] [10.1056/NEJMoa071359](https://doi.org/10.1056/NEJMoa071359)

### ILLUMINATE, 2007:

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 Nov 22;357:2109-22 [17984165] [10.1056/NEJMoa0706628](https://doi.org/10.1056/NEJMoa0706628)

### RADIANCE 2, 2007:

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60 [17630038]

### ILLUSTRATE, 2007:

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16 [17387129]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.